Clinical Trials
16 trialsNCT04294160 2025-12-24
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Novartis
Phase 1 Terminated
NCT04418167 2025-09-03
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
Phase 1 Suspended
NCT03332589 2022-05-20
E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
Spirita Oncology, LLC
Phase 1 Terminated
NCT02110355 2021-03-26
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Kartos Therapeutics, Inc.
Phase 1 Completed
NCT02027961 2019-05-17
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
MedImmune LLC
Phase 1 Completed
NCT01231594 2019-03-22
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
Novartis
Phase 1 Completed
NCT02447939 2018-09-14
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
GlaxoSmithKline
Phase 1 Withdrawn
NCT01767454 2017-11-14
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
GlaxoSmithKline
Phase 1 Completed
NCT01954043 2017-11-14
A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00880321 2017-11-13
A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01262963 2017-11-13
An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01340833 2017-11-13
Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01340846 2017-11-13
A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01582997 2017-11-13
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01738451 2017-11-13
A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors
GlaxoSmithKline
Phase 1 Completed
NCT02082665 2017-07-24
Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam
GlaxoSmithKline
Phase 1 Completed